Results 181 to 190 of about 35,110 (216)

Analysis of Pathways related to Acquisition of Resistance to Cetuximab

Analysis of Pathways related to Acquisition of Resistance to Cetuximab
Thesis or Dissertation 学位記番号 ...
openaire  

Rational combination with PDK1 inhibition overcomes cetuximab resistance in head and neck squamous cell carcinoma. [PDF]

JCI Insight, 2019
Lu H, Lu Y, Xie Y, Qiu S, Li X, Fan Z.
europepmc   +1 more source

miR-302a Inhibits Metastasis and Cetuximab Resistance in Colorectal Cancer by Targeting NFIB and CD44. [PDF]

Theranostics, 2019
Sun L, Fang Y, Wang X, Han Y, Du F, Li C, Hu H, Liu H, Liu Q, Wang J, Liang J, Chen P, Yang H, Nie Y, Wu K, Fan D, Coffey RJ, Lu Y, Zhao X, Wang X.   +19 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

GLUD1 Promotes Cetuximab Resistance in Metastasis Colorectal Cancer

SSRN Electronic Journal, 2021
Background: Colorectal cancer (CRC) is one of the most common causes of cancer mortality worldwide, among which metastatic colorectal cancer (mCRC) is the deadliest one. Cetuximab as a monoclonal antibody targeting epidermal growth factor receptor (EGFR) has improved the survival of mCRC patients.
Ke Peng, Xiaojing Xu, Mengling Liu, Li Liang, Yitao Yuan, Yingyong Hou, Yiyi Yu, Tianshu Liu   +7 more
openaire   +1 more source

Abstract 726: Erlotinib overcomes acquired resistance to cetuximab

Cancer Research, 2011
Abstract The epidermal growth factor receptor (EGFR) is a ubiquitously expressed receptor tyrosine kinase (RTK) and is recognized as a key mediator of proliferation and progression in many human epithelial tumors. Following more than 20 years of preclinical development, five EGFR inhibitors, two monoclonal antibodies and three small ...
Toni M. Brand, Emily F. Dunn, Mari Iida, Rebecca Myers, Chunrong Li, Deric L. Wheeler   +5 more
openaire   +1 more source

The road to resistance: EGFR mutation and cetuximab

Nature Medicine, 2012
Some individuals with colorectal cancer benefit from therapies targeting the epidermal growth factor receptor (EGFR). However, resistance to EGFR blockade inevitably occurs. The characterization of a new mechanism of resistance to the EGFR-specific antibody cetuximab provides clues into how therapeutic strategies might be designed to overcome this ...
BARDELLI, Alberto, Jänne PA
openaire   +1 more source

Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer

Journal of Clinical Oncology, 2010
Personalized cancer medicine based on the genetic milieu of individual colorectal tumors has long been postulated, but until recently this concept was not supported by clinical evidence. The advent of the epidermal growth factor receptor (EGFR) –targeted monoclonal antibodies cetuximab and panitumumab has paved the way to the individualized treatment ...
BARDELLI, Alberto, Siena S.
openaire   +4 more sources

Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial

The Lancet Oncology, 2019
Most head and neck squamous-cell carcinomas (HNSCCs) are driven by p16INK4A inactivation and cyclin D1 overexpression that results in hyperactivation of cyclin-dependent kinase 4 and 6 (CDK4/6), rather than by the human papillomavirus (HPV). Deregulated cyclin D1 expression also causes resistance to EGFR inhibitors.
Douglas, Adkins, Jessica, Ley, Prakash, Neupane, Francis, Worden, Assuntina G, Sacco, Kevin, Palka, Juneko E, Grilley-Olson, Ronald, Maggiore, Noha N, Salama, Kathryn, Trinkaus, Brian A, Van Tine, Conor E, Steuer, Nabil F, Saba, Peter, Oppelt   +13 more
openaire   +2 more sources

Abstract 95: Targeting BRD4 overcomes cetuximab resistance in HNSCC

Cancer Research, 2017
Abstract Background: Nearly 600,000 people are diagnosed with head and neck cancer worldwide and 60% succumb to the disease within 5 years. The epidermal growth factor receptor (EGFR) is a major driver of HNSCC and in 2006 the EGFR monoclonal antibody cetuximab was FDA-approved for HNSCC treatment.
Toni Brand, Yan Zeng, Brandon Leonard, Rachel O' Keefe, Hua Li, Daniel Johnson, Jennifer Grandis, Neil E. Bhola   +7 more
openaire   +1 more source